Peptides, explained: Answers to your top questions
Catching you up on the flood online information
Peptides. are. everywhere. Someone is injecting themselves with a small vial before a workout. A wellness clinic advertises “regenerative peptide therapy.” A podcast host credits a peptide with healing his tendon in two weeks. Google Trends shows searches for “peptides” taking off like a rocket this year.
So what the heck is happening? At the heart of it is a fascinating story about how your body works, what fills the void when science and policy move at different speeds, and whom we trust when we want to heal faster, feel better, and optimize health.
This topic has moved quickly and will continue to do so, leaving many people with questions. Here are the top five we received at YLE, answered. I hope it helps!
A big thanks to Dr. Aaron Kesselheim, a pharmacoepidemiology and pharmacoeconomics expert who somehow always makes time for my random email requests and has a gift for explaining drugs and the complicated regulatory terrain.
What even is a peptide?
Think of peptides as how your body sends text messages. They are short chains of amino acids linked by chemical bonds, and their job is to deliver brief, specific instructions. For example, one peptide chain tells your cells to absorb glucose, and another peptide chain can prompt your brain to release growth hormone. Your body is running thousands of these signals every day.
Scientists figured out that we can write our own versions of these messages in a lab and inject them to trigger responses. Some of the most remarkable drugs in the world are peptides, like:
Insulin, which has kept people with diabetes alive for a century.
Ozempic, which started as a diabetes drug, has proven helpful for systems throughout the body, including the brain, heart, and kidneys. (That said, not all GLP-1 products on the market are FDA-approved. Compounded and gray-market GLP-1 drugs carry risks. Here is a YLE deep dive on GLP-1s.)
Ozempic, which underwent extensive clinical trials, continues to show benefits that surprise us years after its approval. That’s what makes peptides both fascinating and humbling. Even when a peptide drug has one intended recipient, we don’t always know who else is in the chat receiving the message.
The peptides flooding social media are using the same messaging system, but the texts are basically from an unknown number. We don’t fully know who they’re addressed to, which systems receive them, or what those systems do in response, because we lack the scientific evidence.
What does the research say about these early peptides?
“Peptides” is a very broad category, so each one lies on a spectrum ranging from “decades of human research” to “never been tested in humans.”
BPC-157 and TB-500, the two peptides generating a lot of attention right now, sit firmly in the “potentially promising animal studies” category. Rat studies show interesting effects: accelerated tendon and ligament healing, gut lining repair, reduced inflammation across multiple tissue types, and improved muscle recovery. TB-500 has even been studied and subsequently banned for use in racehorses, which tells you something about how seriously the performance world takes it, even without human data.
But animals aren’t humans. Rats heal differently, metabolize compounds differently, and are studied under controlled conditions that don’t reflect the complexity of human biology, health history, or dosing. There are many medicines that look remarkable in animals and fail, sometimes dangerously, in human trials.
For BPC-157, there are a few, very small human pilots, but no randomized controlled trials. TB-500 itself has not been studied in human trials, though its parent molecule (which isn’t identical), thymosin beta-4, has progressed to Phase I trials for specific conditions in China.
Other peptides that you see on social media may not even have evidence from animal studies.
In conclusion, the people currently using these compounds are, in effect, running an uncontrolled experiment on themselves.
Then how can they be sold? And why is everyone talking about peptides right now?
There is a regulatory gray space that has recently experienced a bout of whiplash.
For years, compounding pharmacies (facilities that custom-mix medications for individual patients) served as the primary legal pipeline for peptides like BPC-157 and TB-500. While compounded drugs are not FDA-approved, the FDA permits their sale when a patient has a specific medical need that no existing approved product can meet. Chronic tendon injuries, for example, are notoriously difficult to treat, and patients working closely with their physicians may be open to trying therapies that lack formal human trials. Because compounding pharmacies typically require a doctor’s prescription, patients generally access these drugs under at least some degree of medical supervision.
Then, in late 2023, the FDA moved 19 of the most popular peptides to the Category 2 list, which is essentially a “do not compound” designation. There was growing misuse of telehealth on a scale that demanded a response, and the FDA cited safety concerns, including immune reactions, pancreatitis, and accelerated growth of cancerous cells.
But demand didn’t disappear, and in its place, a “gray market” appeared. Overseas suppliers, like in China, began selling these compounds online, labeled “for research use only” to sidestep FDA jurisdiction. (It would be illegal under the Federal Food, Drug, and Cosmetic Act for a manufacturer to sell an unapproved product in the U.S. market for the “diagnosis, cure, mitigation, treatment, or prevention of disease.”)
Then, on February 27, 2026, HHS Secretary RFK Jr. went on the Joe Rogan podcast and announced that roughly 14 of those 19 restricted peptides would be re-categorized such that the FDA would permit them to be compounded once again. Within hours, posts declared “peptides are legal again,” wellness clinics started marketing aggressively, and money started flowing in.
As of today, though, no formal FDA rule has actually changed. The actual process (rule-making, supply chain readiness, and possibly public comment) will take months, at a minimum. The FDA announced a formal advisory committee meeting for this summer to review whether several peptides should be added back to the compounding available list.
Why do people skeptical of vaccines embrace peptides that have even less human evidence?
At least three strong overlapping forces are at play:
Marketing and association. Peptides have been embraced by the wellness and biohacking world, giving them a “natural” and “holistic” halo. But it’s not just how they are marketed, it’s who is marketing them. Influencers have large, loyal audiences and are a genuine force in shaping health decisions today. Their endorsement carries a kind of peer trust that pharmaceutical companies simply cannot replicate. Big Pharma has lost trust due to overcharging for drugs and overmarking products leading to harm, like Vioxx 20 years ago. Vaccines, by contrast, are associated with Big Pharma that markets them and the government health agencies that recommend them.
Logical fallacies
Nature fallacy. Peptides feel familiar because they already exist in the body, so the perceived risk feels negligible. How dangerous can something be if your body already makes it? But this ignores that dose, delivery method, and context change everything, and that many of the peptides being sold are synthetic analogs rather than identical copies of what your body produces.
Post hoc fallacy. When someone injects a peptide, and their tendon feels better two weeks later, the peptide gets the credit, even though tendons heal on their own, and there was no control group. This is the same logic that drives vaccine skepticism ("Someone I know got the shot and then died"), but applied asymmetrically.
Legitimate grievances. Some support derives from frustrations with conventional medicine’s blind spots, profit motives, and the experience many patients have of being told their chronic pain or slow-healing injury is something they simply have to live with. Peptides, by contrast, offer a sense of agency and a plausible biological mechanism, which is compelling when the standard of care has let you down.
What does this mean for you?
For people managing chronic conditions that haven’t responded to conventional treatment, the cost of physician visits, specialist referrals, and insurance hurdles makes gray-market peptides appealing because they require no prescription and are often cheaper.
Peptides have found an equally eager audience in the wellness and longevity crowd (athletes, biohackers, and optimization-minded people) who see them as a tool for faster recovery, better performance, and aging on their own terms.
But, ultimately, benefits need to outweigh risks. So, here are some important considerations to take into account:
There are some reported and theoretical risks. For example, many peptides are thought to act on pathways important for tissue growth, including blood vessel growth, which should be taken very seriously because these processes drive cancer when they go awry.
Reclassification is not the same as approval. Availability of peptides on the gray market, or even by prescription at a compounding pharmacy, does not mean they have been reviewed by the FDA as safe and effective. That requires years of human clinical trials and a separate, far more rigorous process.
How you access them matters. Having a physician evaluate your specific situation and prescribe through a licensed compounding pharmacy is meaningfully different from self-injecting something ordered online. Unverified sources can contain impurities, be incorrectly dosed, and produce unpredictable reactions that end up costing far more to treat.
Bottom line
Peptides like insulin and GLP-1s have been lifesaving; other compounds may ultimately prove safe and useful for patient care, while others are just biologically implausible. But we are in a wave of enthusiasm and regulatory uncertainty, where people are making health decisions based on limited information, while others profit from it.
That is worth knowing before you click “add to cart.”
Love, YLE
Another big thanks to Dr. Aaron Kesselheim, an expert in pharmacoepidemiology and pharmacoeconomics, who reviewed this post and provided really helpful feedback.
Your Local Epidemiologist (YLE) is founded and operated by Dr. Katelyn Jetelina, MPH PhD—an epidemiologist, wife, and mom of two little girls. YLE reaches over 425,000 people in over 132 countries with one goal: “Translate” the ever-evolving public health science so that people will be well-equipped to make evidence-based decisions. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members. To support the effort, subscribe or upgrade below:
I always look at who is definitely benefiting. Follow the money. But thank you for this reasonable and thorough discussion.
This is so well-written, nuanced, accurate, and not filled with the "anti-" attitude that I've seen from some of your guest writers. Thank you! I look forward to the comments.